pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Gvoke · news · pharmadog
← back to Gvoke
News mentioning Gvoke
12
stories
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
23d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
23d
Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
endpoints
23d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
28d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
28d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
28d
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
